'Cell therapy without cells': Capstan raises $175M to test in vivo CAR-T

Kyle LaHucik

Senior Reporter

Laura Shawver pictures a world 10 years from now where cell therapies are replaced by in vivo CAR-T products. The goal is a cheaper-to-produce, less …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'Cell therapy without cells': Capstan raises $175M to test in vivo CAR-T

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

Eisai terminates Phase 3 trial of Dravet drug, citing recruitment challenges

Trump picks vaccine skeptic Kennedy to lead HHS, in what would be an upheaval of US health policy

Boston Pharmaceuticals hits Phase 2 goals as it tries to keep up with MASH competitors

Evotec gains on Halozyme's takeover proposal

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

'Cell ther­a­py with­out cell­s': Cap­stan rais­es $175M to test in vi­vo CAR-T

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Ei­sai ter­mi­nates Phase 3 tri­al of Dravet drug, cit­ing re­cruit­ment chal­lenges

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Boston Phar­ma­ceu­ti­cals hits Phase 2 goals as it tries to keep up with MASH com­peti­tors

Evotec gains on Halozyme's takeover pro­pos­al

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

'Cell therapy without cells': Capstan raises $175M to test in vivo CAR-T

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

Eisai terminates Phase 3 trial of Dravet drug, citing recruitment challenges

Trump picks vaccine skeptic Kennedy to lead HHS, in what would be an upheaval of US health policy

Boston Pharmaceuticals hits Phase 2 goals as it tries to keep up with MASH competitors

Evotec gains on Halozyme's takeover proposal

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?